PCN208 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION: AN ANALYSIS FROM A SWISS HEALTHCARE SYSTEM PERSPECTIVE

Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.404
https://www.valueinhealthjournal.com/article/S1098-3015(19)32782-2/fulltext
Section Title :
Section Order : 10335
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32782-2&doi=10.1016/j.jval.2019.09.404
HEOR Topics :
Tags :
Regions :